Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy

Abeona Therapeutics (NASDAQ:ABEO) has announced that the US Food and Drug Administration (FDA) has granted the company fast track designation...

Abeona Therapeutics Presents New Preclinical Data of ABO-401

Abeona Therapeutics announced the presentation of new preclinical data on its candidate ABO-401.

Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs

Abeona Therapeutics (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic...

Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA

Abeona Therapeutics (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic...

Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

Abeona Therapeutics (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic...

Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease

Abeona Therapeutics (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic...

Agios Receives FDA Priority Review for New Drug Application: How are Gene Therapy Drug Approvals Impacting Stocks?

INN is taking a look at what other companies have received FDA approval for gene therapy drugs and how the...